Suven Life Sciences Share Price

Suven Life Sciences Share Price

NSE: SUVEN
|
Pharmaceuticals
|
S Cap
₹ 370.05
-₹2.80 (-0.75%)
1D
Last updated 03 Sep, 2026, 10:26 IST

Suven Life Sciences Share Price Today

As of 3 Sep 2026, Suven Life Sciences share price is ₹370.05. The stock opened at ₹374.00, compared to its previous close of ₹372.85. During today's trading session, Suven Life Sciences share price moved in the range of ₹367.75 to ₹378.60, with an average price of ₹373.18 for the day. Looking at its last 52-week, the stock has touched a low of ₹124.11 and a high of ₹403.35. On the performance front, Suven Life Sciences share price has increased by 162.59% over the last six months and is up 70.83% on a year-on-year basis.


₹367.75
0.75% down today
₹378.60
1D LOW
1D HIGH

Suven Life Sciences Returns Calculator


Circuit
L
H
₹298.30
₹447.40
52-week
L
H
₹124.11
₹403.35

About Suven Life Sciences

Suven Life Sciences Share Price
ISIN
INE495B01038
Sector Market Cap
₹ 10,552.3 Cr

Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).

Suven Life Sciences Financial Highlights

  • Revenue: Suven Life Sciences reported revenue of ₹21.04 crore in FY26 vs ₹17.56 crore in FY25. It showed an increase of 19.82% on a yearly basis.
  • Operating Profit: Suven Life Sciences reported an operating loss of ₹276.34 crore in FY26 vs ₹160.75 crore in FY25. It showed a decrease of 71.91% on a year-on-year basis.
  • Net Profit: Suven Life Sciences reported a net loss of ₹276.34 crore in FY26 vs ₹160.75 crore in FY25. It showed a decrease of 71.91% on a yearly basis.

Suven Life Sciences Quarterly Result Highlights

  • Suven Life Sciences reported revenue of ₹11.09 crore in Jun 2026, compared with ₹8.30 crore in Mar 2026, representing an increase of 33.61% on a quarter-on-quarter (QoQ) basis.
  • Suven Life Sciences reported an operating loss of ₹127.61 crore in Jun 2026, compared with ₹45.60 crore in Mar 2026, representing a decrease of 179.85% on a quarter-on-quarter (QoQ) basis.
  • Suven Life Sciences reported a loss of ₹127.61 crore in Jun 2026, compared with ₹45.60 crore in Mar 2026, reflecting a decrease of 179.85% on a QoQ basis.
  • The earnings per share (EPS) of Suven Life Sciences stood at ₹12.13 during Jun 2026.
Know more
Promoters
65.47%
FII
0.48%
Other DII
2.72%
Retail and other
31.32%
Mutual funds
0.01%
Foreign institutions - FII
FII shareholding by period
Mar 20260.91%
Jun 20260.57%
Jul 20260.48%
Aug 20260.48%
Mkt Cap Cr
10,552.30

P/E
-29.95

P/B
15.41

ROE
-46.73%

D/E
0.01

ROCE
-45.42%

Div. Yield
0.00%

EPS(TTM)
-2.41
Turnover
0.01

EV/EBITDA
-30.29

Net Margin
-905.77%

Op. Margin
-823.21%

ROA
-56.46%

Quick Ratio
39.65

Curr. Ratio
59.53
Based on fundamentals, this stock's
Step 5 of 5
Performance
Excellent
Suven Life Scie. outperforming all market indices
Step 1 of 5
Valuation
Overvalued
Suven Life Scie. appears overvalued compared to its peers
Step 3 of 5
Earnings
Neutral
Suven Life Scie. earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Apollo Hospitals1,25,998.0057.6913.2220.48%0.3217.27%692.920.23%0.66103.81
MANIPAL HEALTH ENTERPRI L93,280.00102.925.6810.59%0.469.51%0.000.00%0.000.00
Max Healthcare96,743.7066.409.0013.42%0.0912.97%91.840.20%0.277.37
Fortis Healthcare68,991.9064.456.9710.53%0.2312.56%122.240.11%0.153.05
Aster DM Healthcare66,430.20183.2014.508.48%0.3110.10%53.530.24%0.435.20
Narayana Hrudayalaya39,297.6048.128.6617.76%0.7611.42%127.100.23%0.7624.77
Global Health39,162.5070.379.8114.05%0.0615.26%149.240.03%0.7318.46
Dr. Lal Path Labs32,118.7058.7912.8020.13%0.0825.56%147.341.07%0.9130.45
KRISHNA INST OF MED SCI L31,878.50162.728.4410.74%0.637.99%93.540.00%0.426.52
Poly Medicure17,789.9057.805.8210.37%0.0812.71%301.170.20%0.4833.15

Suven Life Sciences Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹7.11₹6.66₹11.69₹13.54
Other Income₹13.93₹10.90₹21.13₹8.45
Total Revenue₹21.04₹17.55₹32.82₹21.99
Total Expenses₹297.39₹178.30₹146.36₹146.26
Profit Before Tax-₹276.34-₹160.75-₹106.08-₹118.27
Tax₹0.00₹0.00-₹1.00₹0.00
Profit After Tax-₹276.34-₹160.75-₹105.08-₹118.27
EPS - Basic-₹12.13-₹7.37-₹4.82-₹5.42
EPS - Diluted-₹12.13-₹7.37-₹4.82-₹5.42

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹276.34-₹160.75-₹106.08-₹118.27
Income before WC changes-₹282.33-₹164.77-₹128.54-₹126.36
Change in Assets-₹8.79-₹0.92₹4.78₹8.01
Change in Liabilities-₹9.54₹10.98₹2.11₹3.47
Change in WC-₹18.33₹10.07₹6.89₹11.48
Cash flow from Operations-₹299.90-₹155.31-₹115.47-₹115.98
Cash flow from Investing-₹462.11₹154.95₹94.44-₹247.81
Cash flow from Financing₹756.78-₹0.76-₹1.05₹395.54
Total Cash Flow-₹5.23-₹1.12-₹22.09₹31.75
Cash (Start of the year)₹15.03₹14.93₹37.02₹5.27
Cash (End of the year)₹9.80₹13.82₹14.93₹37.02

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹77.51₹59.71₹28.23₹137.32
Current Assets₹546.71₹75.47₹256.67₹251.59
Total Assets₹624.21₹135.18₹284.90₹388.91
Current Liabilities₹18.75₹23.49₹13.52₹11.13
Net Current Asset₹527.96₹51.99₹243.16₹240.46
Non-Current Liabilities₹14.06₹1.71₹1.35₹2.46
Equity Capital₹591.40₹109.99₹270.04₹375.32
Total Equity & Liabilities₹624.21₹135.18₹284.90₹388.91

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹7.11₹6.66₹11.69₹13.54
Other Income₹13.91₹10.73₹21.13₹8.45
Total Revenue₹21.03₹17.38₹32.82₹21.99
Total Expenses₹75.89₹64.46₹49.29₹48.12
Profit Before Tax-₹54.86-₹47.08-₹9.01-₹20.13
Tax₹0.00₹0.00-₹1.00₹0.00
Profit After Tax-₹54.86-₹47.08-₹8.01-₹20.13
EPS - Basic-₹2.41-₹2.16-₹0.37-₹1.13
EPS - Diluted-₹2.41-₹2.16-₹0.37-₹1.13

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax-₹54.86-₹47.08-₹9.01-₹20.13
Income before WC changes-₹60.84-₹51.00-₹31.47-₹28.22
Change in Assets-₹8.79-₹0.92₹4.78₹8.01
Change in Liabilities₹1.16₹3.92-₹0.06-₹1.61
Change in WC-₹7.63₹3.00₹4.73₹6.40
Cash flow from Operations-₹67.71-₹48.60-₹20.56-₹22.92
Cash flow from Investing-₹685.74₹44.21-₹0.68-₹348.82
Cash flow from Financing₹756.78-₹0.76-₹1.05₹395.54
Total Cash Flow₹3.34-₹5.15-₹22.30₹23.79
Cash (Start of the year)₹0.46₹4.40₹26.70₹2.90
Cash (End of the year)₹3.80-₹0.75₹4.40₹26.70

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹990.35₹751.18₹605.34₹619.18
Current Assets₹540.71₹57.71₹246.14₹241.26
Total Assets₹1,531.06₹808.89₹851.48₹860.44
Current Liabilities₹13.63₹7.67₹4.76₹4.54
Net Current Asset₹527.08₹50.04₹241.38₹236.73
Non-Current Liabilities₹14.06₹1.71₹1.35₹2.46
Equity Capital₹1,503.37₹799.51₹845.38₹853.44
Total Equity & Liabilities₹1,531.06₹808.89₹851.48₹860.44
* All values are in INR Crore
Qty
Bid
4
370.05
33
370
13
369.7
47
369.65
125
369.6
Ask
Qty
370.15
50
370.2
40
370.25
10
370.3
18
370.35
30
Bid Total: 222
Ask Total: 148
Buy orders: 60%
Sell orders: 40%
Bearish
1
Neutral
6
Bullish
1
Neutral
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict

RSI (14)
58.77
Neutral

ATR (14)
22.5
Neutral

STOCH(9,6)
34.69
Neutral

STOCH RSI (14)
33.99
Neutral

ADX(9)
45.48
Bearish

UO(9)
48.29
Neutral

ROC(12)
11.95
Bullish

WillR(14)
-37.1
Neutral
Period
Simple value
Exponential vaue

5D
375.91
375.42

10D
372.83
368.85

20D
352.12
356.16

50D
330.17
328.14

100D
284.16
290.38
Volume trend — traded volume by day
3 Sep1L
2 Sep5L
1 Sep8L
31 Aug17L
28 Aug2L
27 Aug2L
Average6L
Compare against other stocks
Suven Life Sciences Share Price
Suven Life Sciences
Pharmaceuticals
Add Stock
Add Another

Suven Life Sciences Share Price FAQs